Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Executive Summary

• Clearmind Medicine announced the publication of a U.S. patent application covering its novel combination therapy of 5‑methoxy‑2‑aminoindane (MEAI) and N‑acylethanolamines (e.g., PEA) for binge behavior disorders.
• The therapy targets multiple addictive behaviors—including alcohol, cocaine, overeating, smoking, compulsive shopping, and problematic sexual conduct—leveraging MEAI’s neuroplastic effects and synergistic action with PEA.
• This filing adds to Clearmind’s growing IP portfolio (now 13 patents related to the SciSparc collaboration) and supports its strategy to develop next‑generation psychedelic‑derived therapeutics for addiction medicine.

Key Details

• Patent Application: U.S. patent application published by the USPTO for the MEAI + PEA combination therapy.
• Therapeutic Targets: Binge behavior disorders such as excessive alcohol consumption, binge eating, smoking, compulsive shopping, and problematic sexual conduct.
• Mechanism of Action: MEAI provides neuroplastic properties that reduce impulsivity and reward‑seeking; PEA adds synergistic pharmacological benefits, together aiming for a safer, more effective treatment than existing options.
• Collaboration Basis: The invention stems from Clearmind’s ongoing partnership with SciSparc Ltd. (Nasdaq: SPRC).
• IP Portfolio Expansion: Brings the total to 13 patent families filed under the SciSparc collaboration, covering indications including alcohol use disorder, cocaine addiction, obesity/weight loss, and depression.
• Preclinical Support: Data indicate MEAI’s efficacy in mitigating addictive behaviors while preserving normal natural reward pathways.
• CEO Quote: “The publication of this U.S. patent application represents yet another advancement in our mission to pioneer safe and effective, next‑generation treatments for binge behaviors.” – Dr. Adi Zuloff‑Shani, CEO.

Notable Quotes

“By combining MEAI’s unique neuroplastic profile with PEA’s synergistic benefits, we’re aiming to address a significant unmet need in addiction medicine. We believe that this strengthens our position as a leader in psychedelic therapeutics and paves the way for additional clinical development.” – Dr. Adi Zuloff‑Shani, CEO, Clearmind Medicine Inc.